目的: 探讨lncRNA RP11-259P1.1在食管鳞状细胞癌（esophageal squamous cell cancer，ESCC）中的表达水平及其与患者临床病理特征和预后的关系。 方法： 收集2012年1月1日至 2016年12月31日西南医科大学附属医院行手术切除的130例ESCC原发病灶及对应癌旁组织标本、人ESCC细胞株KYSE510、Eca109及食管上皮细胞株Het-1A，采用实时荧光定量PCR法检测lncRNA RP11- 259P1.1在ESCC组织及细胞中的表达水平，分析其在组织中表达水平与患者临床病理特征及预后的关系。 结果: lncRNA RP11-259P1.1在ESCC细胞及组织中表达水平显著高于正常管上皮细胞及癌旁组织(均P<0.01）。lncRNA RP11-259P1.1高表达与肿瘤大小、肿瘤分期、淋巴结转移及术前放化疗（CRT）后肿瘤缓解明显相关(均P<0.05), 与患者年龄、性别、肿瘤部位、吸烟状况等无关(均P>0.05)。在63例术前接受新辅助CRT治疗患者中，低表达lncRNA RP11-259P1.1患者与高表达患者比较： （1）病理完全缓解率明显升高（60.00% vs 21.21%，P<0.01）;（2）术前CRT的疗效更佳（P<0.05）； （3）中位无进展生存时间和生存时间均明显延长[(28.00±2.47) vs (17.00±1.90)个月，(41.57±2.45) vs (30.00±2.55)个月；均P<0.01]。lncRNA RP11-259P1.1为ESCC患者独立的预后因素(P<0.05)。 结论: lncRNA RP11-259P1.1可能是ESCC潜在的预后和术前CRT疗效评价的分子标志物，低表达lncRNARP11-259P1.1的患者术前给予CRT疗效更佳。

Objective: To investigate lncRNA RP11-259P1.1 expression in esophageal squamous cell carcinoma (ESCC) and to explore its correlation with clinicopathological features and prognosis. Methods: 130 cases of prima-ry ESCC cancer tissues and the corresponding paracancerous tissues resected during surgery from January 1, 2012to December 31, 2016 at the Affiliated Hospital of Southwest Medical University, as well as human ESCC cell lines KYSE510, Eca109 and esophageal epithelial cell line Het-1A were collected for this study. The method of quantita-tive real-time polymerase chain reaction (qPCR) was used to measure lncRNA RP11-259P1.1 expression in speci-mens and cells, and the association between lncRNA RP11-259P1.1 expression in speciments and clinicopathologi-cal features or prognosis was analyzed. Results: The expression of lncRNA RP11-259P1.1 in esophageal cancer cells and cancer tissues was significantly higher than that in normal esophageal epithelial cells and para-cancerous tissues (all P＜0.01). High expression of lncRNA RP11-259P1.1 was significantly associated with tumor size, TNM stage, lymph node metastases and chemoradiotherapy sensitivity (CRT) (P<0.05), but not associated with ages, gen-der, tumor location, smoking (P>0.05). In 63 cases of patients receiving neoadjuvant radiochemotherapy (CRT+S),by comparing patients with high lncRNA RP11-259P1.1 expression and low expression, (1) pathological complete remission (pCR) rate in low expression patients was significantly increased (60% vs 21.21%, P<0.05); (2) the treat-ment efficacy of pre-operative CRT in patients with low expression was better (P<0.05); (3) median progress-free survival (PFS) and overall survival (OS) of patients with low expression was significantly prolonged ([28.00±2.47]months vs [17.00±1.90] months，P<0.01; [41.57±2.45] months vs [30.00±2.55] months，P<0.01). lncRNA RP11-259P1.1 can be used as a prognostic factor for patients with esophageal cancer (P<0.05). Conclusion: The expres-sion of lncRNA RP11-259P1.1 could serve as a potential molecular marker to predict the prognosis and pre-opera-tive CRT treatment efficacy of ESCC patients, and patients with low lncRNA PR11-259P1.1 expression might achieve a better treatment efficacy from pre-operative CRT.

国家自然科学基金资助项目（No.31300946）